Literature DB >> 23931026

Quality of life after pulmonary resections.

Robert J Cerfolio1, Ayesha S Bryant.   

Abstract

Quality of life (QOL) is an important component of the conversation between any physician and patient. It is especially important between a surgeon and an operative candidate when considering treatment of lung cancer. Patients want reassurance that after removal of part of their lung that not only will they be cancer-free but also that they will be able to breathe well even when active. They do not want to be left physically or mentally handicapped. Recent studies have also shown the correlation between QOL and survival after resection. In this article the literature concerning QOL after pulmonary resection is reviewed.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Morbidity; Pulmonary resection; Quality of life (QOL)

Mesh:

Year:  2013        PMID: 23931026     DOI: 10.1016/j.thorsurg.2013.05.004

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  3 in total

1.  Initial results of robot-assisted thoracoscopic surgery in Japan.

Authors:  Hiroshige Nakamura; Takashi Suda; Norihiko Ikeda; Morihito Okada; Hiroshi Date; Makoto Oda; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-07-18

2.  Changes in Health-Related Quality of Life During Rehabilitation in Patients With Operable Lung Cancer: A Feasibility Study (PROLUCA).

Authors:  Maja S Sommer; Karen Trier; Jette Vibe-Petersen; Karl B Christensen; Malene Missel; Merete Christensen; Klaus R Larsen; Seppo W Langer; Carsten Hendriksen; Paul F Clementsen; Jesper H Pedersen; Henning Langberg
Journal:  Integr Cancer Ther       Date:  2016-10-03       Impact factor: 3.279

3.  The effect of comprehensive rehabilitation program plus chemotherapy on quality of life in patients with postoperative non-small-cell lung cancer: study protocol of a multicenter randomized clinical trial.

Authors:  Jialin Yao; Lijing Jiao; Yiqing Yao; Yan Lu; Jun Shi; Jiaqi Li; Peiqi Chen; Ling Xu; Yabin Gong
Journal:  Trials       Date:  2020-04-03       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.